Literature DB >> 16200576

Tuberculosis associated with therapy against tumor necrosis factor alpha.

Kevin L Winthrop1, Jeffrey N Siegel, John Jereb, Zachary Taylor, Michael F Iademarco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16200576     DOI： 10.1002/art.21382

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  27 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 2.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 4.  Infectious complications associated with monoclonal antibodies and related small molecules.

Authors:  Edsel Maurice T Salvana; Robert A Salata
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

Review 5.  Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.

Authors:  Kevin L Winthrop; Michael Iseman
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

Review 6.  Preventing and treating biologic-associated opportunistic infections.

Authors:  Kevin L Winthrop; Tom Chiller
Journal:  Nat Rev Rheumatol       Date:  2009-07       Impact factor: 20.543

Review 7.  Tumor necrosis factor inhibitors and infection complications.

Authors:  Monica Crawford; Jeffrey R Curtis
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

8.  Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.

Authors:  Morihito Takita; Shinichi Matsumoto; Masayuki Shimoda; Daisuke Chujo; Takeshi Itoh; Jeffrey A Sorelle; Kerri Purcell; Nicholas Onaca; Bashoo Naziruddin; Marlon F Levy
Journal:  Clin Transplant       Date:  2012 Sep-Oct       Impact factor: 2.863

9.  A case of tuberculous arthritis following the use of etanercept.

Authors:  Seung Won Choi; Jong Joon Ahn; Young Tae Hwang; Sang Hoon Koh; Sung Do Cho
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

Review 10.  Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.

Authors:  Kevin L Winthrop; Eric Chang; Shellie Yamashita; Michael F Iademarco; Philip A LoBue
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.